Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes

Pharmacogenetics and Genomics

Volumn 22, Issue 11, 2012, Pages 807-811

  Teo, Celine ^a   Zai, Clement ^a   Borlido, Carol ^a   Tomasetti, Carmine ^b   Strauss, John ^a   Shinkai, Takahiro ^c   Le Foll, Bernard ^a   Wong, Albert ^a   Kennedy, James L ^a   De Luca, Vincenzo ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

antipsychotics; gene; polymorphism; schizophrenia; treatment resistance

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; FEMALE; GENE; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NALCN GENE; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; SCHIZOPHRENIA;

EID: 84867562644     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283586c04     Document Type: Article

References (19)

1. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997; 23:663-674.
2. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980; 6:70-87.
3. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993; 50:369-376.
4. Weiss EL, Longhurst JG, Bowers MB Jr, Mazure CM. Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine. J Clin Psychopharmacol 1999; 19:378-380.
5. Castro AP, Elkis H. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. Rev Bras Psiquiatr 2007; 29:207-212.
6. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993; Suppl:13-17.
7. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988; 24:62-67.
8. Meltzer H, Kostakoglu A. Treatment resistant schizophrenia. In: Liberman J, Murray R, editors. Comphrehensive care of schizophrenia: a textbook of clinical management. London: Martin Dunitz; 2001. pp. 181-203.
9. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152:183-190.
10. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161 (Suppl): 1-56.
11. Crosthwaite CG, Reveley MA. Structural imaging and treatment response in schizophrenia. In: Reveley MA, editor. Psychopharmacol Schizophr. London: Arnold; 2000. pp. 89-108.
12. Friedman L, Lys C, Schulz SC. The relationship of structural brain imaging parameters to antipsychotic treatment response: a review. J Psychiatry Neurosci 1992; 17:42-54.
13. Sharma T, Kerwin R. Biological determinants of difficult to treat patients with schizophrenia. Br J Psychiatry Suppl 1996; 31:5-9.
14. De Luca V, Souza RP, Panariello F, Meltzer HY. Genetic studies in treatmentresistant schizophrenia. In: Elkis H, Meltzer HY, editors. Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel: Karger; 2010; 26:52-62.
15. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 2003; 164:1567-1587.
16. Wang KS, Liu XF, Aragam N. A genome-wide meta-analysis identifies novel loci associated with schizophrenia and bipolar disorder. Schizophr Res 2010; 124:192-199.
17. Shibata H, Joo A, Fujii Y, Tani A, Makino C, Hirata N, et al. Association study of polymorphisms in the GluR5 kainate receptor gene (GRIK1) with schizophrenia. Psychiatr Genet 2001; 11:139-144.
18. Giegling I, Drago A, Dolz?an V, Plesnic? ar BK, Scha fer M, Hartmann AM, et al. Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. Pharmacogenet Genomics 2011; 21: 206-216.
19. Inada T, Nakamura A, Iijima Y. Relationship between catechol- Omethyltransferase polymorphism and treatment-resistant schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 120B:35-39.